Transparency Market Research in its new report titled, “Whipple’s Disease Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the Whipple’s disease market. The TMR report anticipates that the entry of novel, highly priced therapies and high unmet needs will drive the Whipple’s disease market during the forecast period i.e, 2018-2026. More highly-priced therapies are expected during the forecast period. Kalydeco for cystic fibrosis and exon-skipping therapies for duchenne muscular dystrophy are the new therapies introduced in the market. Competitive activity is increasing as larger companies realize the rewards of investing in orphan therapeutics. High unmet needs and low competition in several regions is expected to attract more companies to the market in the near future. The clinical studies for the molecules receiving the funding from the U.S. government for the rare disease lead to increase in development of molecules, says the report.
The TMR report has segmented the global Whipple’s disease market based on type of diagnosis, type of treatment, and end-user. Based on type of treatment, the global Whipple’s disease market is divided into medications, supplements, and others. The medications segment can be classified into ceftriaxone (Rocephin), meropenem (Merrem I.V.), penicillin G (Pfizerpen), streptomycin (Streptomycin), doxycycline (Vibramycin), trimethoprim with sulfamethoxazole (Septra, Bactrim), and hydroxychloroquine (Plaquenil), and others. The supplements segment is categorized into vitamin supplements, iron supplements, mineral supplements, and others. In terms of type of diagnosis, the global Whipple’s disease market is segmented into non-specific diagnosis, specific diagnosis, and indirect diagnosis. Non-specific diagnosis includes physical exam, blood tests, endoscopy, histologic study by specific staining, and electron microscopy. Specific diagnosis includes immune-histochemical diagnosis, molecular diagnosis, and culture. Indirect diagnosis includes indirect immunofluorescence and enzyme-linked immunosorbent assay.
Geographically, the Whipple’s disease market is segmented in five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for major share of the Whipple’s disease market. According to Research Office Legislative Council Secretariat report there are over 30 million people suffering from rare diseases in the U.S. The strong focus on research and development, the government aids to promote R&D, such as research grants, tax credits and fee waivers contribute to the growth of the market. As a result, over 4,171 drugs have been designated orphan drug status in the U.S. as of June 2017. In addition, favorable reimbursement offered by the government and private payers for the treatment of rare diseases contributes to the market growth in the region. Some of the major players operating in the global market are profiled in this report to give a better competitive analysis of the market and these include F. Hoffmann-La Roche Ltd., Pfizer, Inc., Bristol-Myers Squibb Company, and Sun Pharmaceutical Industries Limited.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
